Some success has been achieved in recent years in establishing the clinical utility of the pharmacogenetic testing though it remains questionable whether it is cost- effective or not.
Fagerness, J., Fonseca, E., Hess, G. P., Scott, R., Gardner, K. R., Koffler, M., . . . Lombard, J. (2014). Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. American Journal of Managed Care, 20(5), e146-156.
This is a recent article published that notes a cost savings of 462$ over a 4 month period/ patient. More studies are coming out regarding cost effectiveness it seems...
This is important information in reimbursement for testing!
Julie
Jiang M, You J H S. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy[J]. Expert opinion on pharmacotherapy, 2015, 16(5): 771-779.
This is really an important question!
I think whether genotype-guided therapy is cost-effective depends the studied topic. The upper paper is about cost-effectiveness of genotype-guided antiplatelet therapy in ACS patients for your reference.
Minghuan
- Badges
- Science topic
- Similar topics
- Biological Science
- Anatomy
- Tissue